198 related articles for article (PubMed ID: 32317292)
1. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
[TBL] [Abstract][Full Text] [Related]
3. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
Nicholaou T; Chen W; Davis ID; Jackson HM; Dimopoulos N; Barrow C; Browning J; Macgregor D; Williams D; Hopkins W; Maraskovsky E; Venhaus R; Pan L; Hoffman EW; Old LJ; Cebon J
Cancer Immunol Immunother; 2011 Nov; 60(11):1625-37. PubMed ID: 21698545
[TBL] [Abstract][Full Text] [Related]
4. NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Chen JL; Dawoodji A; Tarlton A; Gnjatic S; Tajar A; Karydis I; Browning J; Pratap S; Verfaille C; Venhaus RR; Pan L; Altman DG; Cebon JS; Old LL; Nathan P; Ottensmeier C; Middleton M; Cerundolo V
Int J Cancer; 2015 Mar; 136(6):E590-601. PubMed ID: 25081390
[TBL] [Abstract][Full Text] [Related]
5. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.
Schnurr M; Orban M; Robson NC; Shin A; Braley H; Airey D; Cebon J; Maraskovsky E; Endres S
J Immunol; 2009 Feb; 182(3):1253-9. PubMed ID: 19155470
[TBL] [Abstract][Full Text] [Related]
6. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Davis ID; Chen W; Jackson H; Parente P; Shackleton M; Hopkins W; Chen Q; Dimopoulos N; Luke T; Murphy R; Scott AM; Maraskovsky E; McArthur G; MacGregor D; Sturrock S; Tai TY; Green S; Cuthbertson A; Maher D; Miloradovic L; Mitchell SV; Ritter G; Jungbluth AA; Chen YT; Gnjatic S; Hoffman EW; Old LJ; Cebon JS
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10697-702. PubMed ID: 15252201
[TBL] [Abstract][Full Text] [Related]
7. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
[TBL] [Abstract][Full Text] [Related]
8. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
9. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.
Klein O; Davis ID; McArthur GA; Chen L; Haydon A; Parente P; Dimopoulos N; Jackson H; Xiao K; Maraskovsky E; Hopkins W; Stan R; Chen W; Cebon J
Cancer Immunol Immunother; 2015 Apr; 64(4):507-18. PubMed ID: 25662405
[TBL] [Abstract][Full Text] [Related]
10. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
[TBL] [Abstract][Full Text] [Related]
11. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Gibney GT; Kudchadkar RR; DeConti RC; Thebeau MS; Czupryn MP; Tetteh L; Eysmans C; Richards A; Schell MJ; Fisher KJ; Horak CE; Inzunza HD; Yu B; Martinez AJ; Younos I; Weber JS
Clin Cancer Res; 2015 Feb; 21(4):712-20. PubMed ID: 25524312
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
13. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
[TBL] [Abstract][Full Text] [Related]
14. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.
Silva A; Mount A; Krstevska K; Pejoski D; Hardy MP; Owczarek C; Scotney P; Maraskovsky E; Baz Morelli A
J Immunol; 2015 Mar; 194(5):2199-207. PubMed ID: 25646304
[TBL] [Abstract][Full Text] [Related]
15. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
16. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.
Mahipal A; Ejadi S; Gnjatic S; Kim-Schulze S; Lu H; Ter Meulen JH; Kenney R; Odunsi K
Cancer Immunol Immunother; 2019 Jul; 68(7):1211-1222. PubMed ID: 31069460
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.
Lattanzi M; Han J; Moran U; Utter K; Tchack J; Sabado RL; Berman R; Shapiro R; Huang HH; Osman I; Bhardwaj N; Pavlick AC
J Immunother Cancer; 2018 May; 6(1):38. PubMed ID: 29773080
[TBL] [Abstract][Full Text] [Related]
18. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.
Mischo A; Bubel N; Cebon JS; Samaras P; Petrausch U; Stenner-Liewen F; Schaefer NG; Kubuschok B; Renner C; Wadle A
Int J Oncol; 2011 Jul; 39(1):287-94. PubMed ID: 21573493
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
20. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
